Log in

NASDAQ:CCXI - ChemoCentryx Stock Price, Forecast & News

$31.28
+0.23 (+0.74 %)
(As of 12/8/2019 04:00 PM ET)
Today's Range
$29.50
Now: $31.28
$31.61
50-Day Range
$7.58
MA: $13.31
$31.28
52-Week Range
$6.16
Now: $31.28
$36.88
Volume658,481 shs
Average Volume2.53 million shs
Market Capitalization$1.82 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.15
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CCXI
CUSIP16383L10
Phone650-210-2900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$42.88 million
Book Value$0.29 per share

Profitability

Net Income$-37,970,000.00
Net Margins-143.30%

Miscellaneous

Employees76
Market Cap$1.82 billion
Next Earnings Date3/9/2020 (Estimated)
OptionableOptionable

Receive CCXI News and Ratings via Email

Sign-up to receive the latest news and ratings for CCXI and its competitors with MarketBeat's FREE daily newsletter.


ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions

What is ChemoCentryx's stock symbol?

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

How were ChemoCentryx's earnings last quarter?

ChemoCentryx Inc (NASDAQ:CCXI) announced its earnings results on Monday, November, 4th. The biopharmaceutical company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.06. The biopharmaceutical company earned $10.58 million during the quarter, compared to the consensus estimate of $7.83 million. ChemoCentryx had a negative return on equity of 88.76% and a negative net margin of 143.30%. View ChemoCentryx's Earnings History.

When is ChemoCentryx's next earnings date?

ChemoCentryx is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for ChemoCentryx.

What price target have analysts set for CCXI?

7 equities research analysts have issued 1 year target prices for ChemoCentryx's stock. Their forecasts range from $22.00 to $56.00. On average, they anticipate ChemoCentryx's stock price to reach $41.33 in the next twelve months. This suggests a possible upside of 32.1% from the stock's current price. View Analyst Price Targets for ChemoCentryx.

What is the consensus analysts' recommendation for ChemoCentryx?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ChemoCentryx.

What are Wall Street analysts saying about ChemoCentryx stock?

Here are some recent quotes from research analysts about ChemoCentryx stock:
  • 1. According to Zacks Investment Research, "ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. " (11/28/2019)
  • 2. HC Wainwright analysts commented, "We base our $23 price target on probability adjusted revenue forecasts for avacopan in AAV and C3G. We use the net present value of our revenue forecast through 2028, apply a 30% probability of success (POS) for avacopan in AAV, a 25% POS for avacopan in C3G, a 3x price/sales multiple, and use our estimated fully diluted year end 2019 net cash of $2.54/share to arrive at our price target. Our P/S multiple of 3x is in-line with ChemoCentryx’s peers that range between 2-5x." (5/7/2019)

Has ChemoCentryx been receiving favorable news coverage?

News articles about CCXI stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. ChemoCentryx earned a news sentiment score of 0.9 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for ChemoCentryx.

Are investors shorting ChemoCentryx?

ChemoCentryx saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 3,250,000 shares, an increase of 6.2% from the October 31st total of 3,060,000 shares. Based on an average daily trading volume, of 415,100 shares, the short-interest ratio is presently 7.8 days. Approximately 8.0% of the shares of the stock are sold short. View ChemoCentryx's Current Options Chain.

Who are some of ChemoCentryx's key competitors?

What other stocks do shareholders of ChemoCentryx own?

Who are ChemoCentryx's key executives?

ChemoCentryx's management team includes the folowing people:
  • Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman (Age 60)
  • Ms. Susan M. Kanaya, Exec. VP, Chief Financial & Admin. Officer and Sec. (Age 56)
  • Dr. Rajinder Singh, Sr. VP of Research (Age 52)
  • Dr. Jan L. Hillson M.D., Sr. VP of Drug Devel. (Age 66)
  • Dr. Markus J. Cappel, Sr. VP, Chief Bus. Officer & Treasurer (Age 58)

Who are ChemoCentryx's major shareholders?

ChemoCentryx's stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (1.30%), BB&T Securities LLC (0.23%), Squarepoint Ops LLC (0.21%), Assenagon Asset Management S.A. (0.21%), Alps Advisors Inc. (0.20%) and Man Group plc (0.12%). Company insiders that own ChemoCentryx stock include Geoffrey M Parker, Markus J Cappel, Plc Glaxosmithkline, Rajinder Singh, Susan M Kanaya and Thomas J Schall. View Institutional Ownership Trends for ChemoCentryx.

Which institutional investors are selling ChemoCentryx stock?

CCXI stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Squarepoint Ops LLC, Man Group plc, Barclays PLC, BB&T Securities LLC and Alps Advisors Inc.. Company insiders that have sold ChemoCentryx company stock in the last year include Geoffrey M Parker, Markus J Cappel, Rajinder Singh, Susan M Kanaya and Thomas J Schall. View Insider Buying and Selling for ChemoCentryx.

Which institutional investors are buying ChemoCentryx stock?

CCXI stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., California Public Employees Retirement System, Metropolitan Life Insurance Co NY and SG Americas Securities LLC. View Insider Buying and Selling for ChemoCentryx.

How do I buy shares of ChemoCentryx?

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ChemoCentryx's stock price today?

One share of CCXI stock can currently be purchased for approximately $31.28.

How big of a company is ChemoCentryx?

ChemoCentryx has a market capitalization of $1.82 billion and generates $42.88 million in revenue each year. The biopharmaceutical company earns $-37,970,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. ChemoCentryx employs 76 workers across the globe.View Additional Information About ChemoCentryx.

What is ChemoCentryx's official website?

The official website for ChemoCentryx is http://www.chemocentryx.com/.

How can I contact ChemoCentryx?

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]


MarketBeat Community Rating for ChemoCentryx (NASDAQ CCXI)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  258 (Vote Outperform)
Underperform Votes:  241 (Vote Underperform)
Total Votes:  499
MarketBeat's community ratings are surveys of what our community members think about ChemoCentryx and other stocks. Vote "Outperform" if you believe CCXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CCXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Featured Article: Investing in Growth Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel